KLK6
KLK6 (Kallikrein-Related Peptidase 6)[edit | edit source]
KLK6, also known as kallikrein-related peptidase 6, is a serine protease enzyme encoded by the KLK6 gene in humans. It is part of the kallikrein family, which consists of 15 serine proteases with diverse physiological functions. KLK6 is predominantly expressed in the central nervous system, but it is also found in other tissues such as the skin, breast, and ovaries.
Structure and Function[edit | edit source]
KLK6 is synthesized as a preproenzyme and undergoes post-translational modifications to become an active enzyme. The active form of KLK6 is involved in the degradation of extracellular matrix components, which is crucial for tissue remodeling and repair. It has been implicated in the regulation of cell migration, inflammation, and apoptosis.
Clinical Significance[edit | edit source]
KLK6 has been studied for its role in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Elevated levels of KLK6 have been observed in the cerebrospinal fluid of patients with these conditions, suggesting its potential as a biomarker for neurodegenerative diseases.
In addition to its role in the nervous system, KLK6 is also being investigated for its involvement in cancer progression. It has been found to be overexpressed in certain types of breast cancer and ovarian cancer, where it may contribute to tumor growth and metastasis.
Mechanism of Action[edit | edit source]
KLK6 exerts its effects by cleaving specific peptide bonds in target proteins. This proteolytic activity is regulated by inhibitors and activators that modulate its function in different physiological contexts. The diagram on the right illustrates the degradation mechanism of KLK6, highlighting its interaction with various substrates and inhibitors.
Research and Therapeutic Potential[edit | edit source]
Ongoing research is focused on understanding the precise role of KLK6 in health and disease. Therapeutic strategies targeting KLK6 activity are being explored, particularly in the context of neuroprotection and cancer therapy. Inhibitors of KLK6 are being developed to modulate its activity in pathological conditions.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
